Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice
DJ Gladstone, SE Black - Cmaj, 2001 - Can Med Assoc
TISSUE PLASMINOGEN ACTIVATOR (TPA) INJECTED INTRAVENOUSLY within 3 hours of
symptom onset has emerged as a treatment option for acute ischemic stroke. Although …
symptom onset has emerged as a treatment option for acute ischemic stroke. Although …
Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data
GD Graham - Stroke, 2003 - Am Heart Assoc
Background and Purpose—Concerns persist regarding the safety of tissue plasminogen
activator (tPA) therapy for acute ischemic stroke. Numerous case series of clinical …
activator (tPA) therapy for acute ischemic stroke. Numerous case series of clinical …
Intravenous thrombolysis for acute ischemic stroke within 3 hours versus between 3 and 4.5 hours of symptom onset
NT Cheng, AS Kim - The Neurohospitalist, 2015 - journals.sagepub.com
Data from randomized clinical trials have supported the safety and efficacy of intravenous
tissue-type plasminogen activator (IV tPA) for acute ischemic stroke when administered …
tissue-type plasminogen activator (IV tPA) for acute ischemic stroke when administered …
Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA)
A Eissa, I Krass, BV Bajorek - Journal of clinical pharmacy and …, 2012 - Wiley Online Library
What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator
(tPA) is the only available evidence‐based treatment for acute ischaemic stroke; however, its …
(tPA) is the only available evidence‐based treatment for acute ischaemic stroke; however, its …
Intravenous thrombolytic therapy for acute ischemic stroke: Weighing the risks and benefits of tissue plasminogen activator
RL Koller, DC Anderson - Postgraduate medicine, 1998 - Taylor & Francis
PREVIEW Intravenous tissue plasminogen activator (tPA) is an important intervention in the
treatment of acute ischemic stroke. However, if not administered according to strict …
treatment of acute ischemic stroke. However, if not administered according to strict …
Intravenous tissue plasminogen activator for stroke: a review of the ECASS III results in relation to prior clinical trials
CA Cronin - The Journal of emergency medicine, 2010 - Elsevier
Background: Intravenous tissue plasminogen activator (IV tPA) is currently approved by the
Food and Drug Administration for use in acute ischemic stroke patients up to 3 h from …
Food and Drug Administration for use in acute ischemic stroke patients up to 3 h from …
Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice
Background and Purpose—The feasibility, safety, and efficacy of intravenous tissue
plasminogen activator (t-PA) for patients with acute ischemic stroke in clinical practice need …
plasminogen activator (t-PA) for patients with acute ischemic stroke in clinical practice need …
Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator
VK Sharma, G Kawnayn, N Sarkar - Expert Review of …, 2013 - Taylor & Francis
Intravenous tissue plasminogen activator (IV-TPA), administered within 4.5 h of symptom
onset, is the only therapeutic agent approved for achieving arterial recanalization in acute …
onset, is the only therapeutic agent approved for achieving arterial recanalization in acute …
Intravenous tissue plasminogen activator for acute ischemic stroke: a Canadian hospital's experience
KM Chapman, AR Woolfenden, D Graeb… - Stroke, 2000 - Am Heart Assoc
Background and Purpose—In the United States, tissue plasminogen activator (tPA) was
approved for treatment of acute ischemic stroke in 1996. Its use has only recently been …
approved for treatment of acute ischemic stroke in 1996. Its use has only recently been …
Current and future use of intravenous thrombolysis for acute ischemic stroke
L Elijovich, JY Chong - Current atherosclerosis reports, 2010 - Springer
Stroke is a common and disabling condition. Intravenous tissue plasminogen activator (tPA)
administered within 3 h of symptom onset is the standard therapy for eligible patients with …
administered within 3 h of symptom onset is the standard therapy for eligible patients with …